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JoObjectives: This study evaluated the effectiveness of a
structured multidisciplinary risk assessment and
management programme for patients with hypertension
(RAMP-HT) who were managed in public primary care
clinics but had suboptimal blood pressure (BP) control in
improving BP, LDL-cholesterol (LDL-C) and predicted 10-
year cardiovascular disease (CVD) risk after 12 months of
intervention.
Methods: A total of 10 262 hypertension patients with
suboptimal BP despite treatment, aged less than 80 years
and without existing CVD were enrolled in RAMP-HT
between October 2011 and March 2012 from public
general out-patient clinics in Hong Kong. Their clinical
outcomes and predicted 10-year CVD risk were compared
with a matched cohort of hypertension patients who were
receiving usual care in general out-patient clinics without
any RAMP-HT intervention by propensity score matching.
Multivariable linear and logistic regressions were used to
determine the independent effectiveness of RAMP-HT after
adjusting for potential confounding variables.
Results: Compared with the usual care group after 12
months, significantly greater proportions of RAMP-HT
participants achieved target BP (i.e. BP<140/90mmHg)
(OR¼1.18, P<0.01) and LDL-C levels (i.e. <3.4mmol/l for
patients with CVD risk 20% or <2.6mmol/l for CVD risk
>20%) (OR¼1.13, P<0.01). RAMP-HT participants also
had significantly greater reduction in predicted 10-year
CVD risk by 0.44% (coefficient¼0.44, P<0.01).
Conclusion: The structured multidisciplinary RAMP-HT was
more effective than usual care in achieving target BP, LDL-
C and reducing predicted 10-year CVD risk in public
primary care patients with suboptimal hypertension control
after 12 months of intervention. A long-term follow-up
should be conducted to confirm whether the improvement
in clinical outcomes can be translated into actual
reductions in CVD complications and mortalities and
whether such approach is cost-effective.
Keywords: cardiovascular disease risk, hypertension,
primary care, risk assessment, risk management, risk
stratification Copyright © 2017 Wolters Kluwer
urnal of HypertensionAbbreviations: BP, blood pressure; CMS, Clinical
Management System; CVD, cardiovascular disease; GOPCs,
general out-patient clinics; HA, Hospital Authority; HT,
hypertension; LDL-C, LDL-cholesterol; NNT, number
needed to treat; RAMP-HT, risk assessment and
management programme for hypertension; TC/HDL-C
ratio, total cholesterol-to-HDL-cholesterol ratio; TG,
triglycerideINTRODUCTIONH
ypertension is a global public health issue of the
21st century [1], affecting more than one-third of
the world’s population [2]. Blood pressure (BP)
optimization has been an important management goal for
healthcare providers to prevent hypertension-related com-
plications and mortality. An array of treatment options,
including pharmacological agents and lifestyle modification
such as dietary approaches to stop hypertension, exercise,
weight reduction, smoking cessation and moderation of
alcohol consumption, had proven efficacy in lowering BP
and reducing long-term hypertension complications [3–5].
However, successful implementation of these multifaceted
interventions in the real-world clinical setting can be chal-
lenged by many factors, such as difficult accesses to health-
care, financial constraints of patients and the healthcare Health, Inc. All rights reserved.
DOI:10.1097/HJH.0000000000001177
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ence to interventions and follow-ups, doctors’ inertia to
adjust medication or make referral to allied health services,
and confounding or even contrasting recommendations
from international guidelines regarding ‘optimal’ treatment
threshold of BP and other comorbid cardiovascular disease
(CVD) risk factors [6,7]. Various interventions had been
explored to address these barriers, including educational
intervention directed to the patients or the physicians,
health profession–led (nurse or pharmacist) care, organiz-
ation interventions and appointment reminder system [8].
Among these different interventions, structured algorithm-
driven health profession–led care involving prescription
adjustment and multidisciplinary care were shown to
favour BP control [8–10]. However, evidence on the effects
of multidisciplinary care for patients with hypertension was
still sparse and lacked generalizability.
In addition to BP control, assessment andmanagement of
total CVD risk of hypertension patients has been advocated
internationally as a holistic and cost-effective way to achieve
maximal prevention or reduction in CVD and resultant
mortalities [4,11–13]. A prospective trial on CVD-risk strat-
ification and risk-guided intervention involving 7090 hyper-
tensionpatientsmanaged inprimary care in theUnited States
demonstrated that the implementation of CVD-risk stratifi-
cation and intervention was associated with a 12-mmHg
reduction in SBP over 10 years [14]. In Canada, the Cardio-
vascular Health Awareness Program confirmed that compre-
hensive screening and management via stratification of risk
factors for hypertension patients reduced CVD mortality
compared with usual care [15]. Mendis also reported that
CVD risk management led to greater decrease in SBP, DBP
and somebehavioural changes even in low-resource settings
[16]. However, these studies focused on CVD-risk stratifica-
tion and risk-guided management by physicians; multidisci-
plinary team care was not employed nor evaluated.
Up to date, evidence is lacking in the effectiveness of
structured protocol-driven intervention programme for
hypertension patients in the primary care setting that
encompasses both multidisciplinary care and CVD-risk
stratification and management. This study aimed at eval-
uating the effectiveness of the risk assessment and man-
agement programme for patients with hypertension
(RAMP-HT), a structured CVD-risk assessment and coor-
dinated multidisciplinary management programme using
readily available resources among public primary care
clinics in Hong Kong, for hypertension patients with
suboptimal BP control despite pharmacological treatment
or lifestyle intervention in terms of clinical outcomes and
predicted long-term CVD risks after 12 months of inter-
vention. This was the first study to provide imperative
translational evidence of CVD-risk stratification and risk-
specific management delivered by a multidisciplinary
team as an additional but integrated service to usual care
for Chinese hypertension patients in the real-world
primary care setting.
METHODS
We conducted a longitudinal cohort study to compare the
changes in clinical outcomes and predicted long-term CVD Copyright © 2017 Wolters Kluwe
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the usual care group.
The RAMP-HT is a territory-wide quality improvement
programme initiated by the Hospital Authority of Hong
Kong, which manages over 200 000 people with hyperten-
sion without diabetes mellitus in Hong Kong, to enhance
care of hypertension patients in the public primary care
setting. Patients with hypertension who are aged less than
80 years, without existing CVD or diabetes mellitus, cur-
rently receiving usual care treatment (either pharmacother-
apy or lifestyle interventions) from a public primary care
clinic [i.e. general out-patient clinic (GOPC)] but still have
suboptimal BP control (i.e. BP 140/90mmHg) are tar-
geted, although all hypertension patients managed under
GOPC are served. From October 2011 to March 2012, the
RAMP-HT was piloted in five of the seven clusters in Hong
Kong. Details of the RAMP-HT programme have been
reported elsewhere [17].
In summary, the enrolled patients underwent standar-
dized CVD-risk assessment, hypertensive complication
screening and assessment on adherence to medications
and lifestyle by registered nurses during the RAMP-HT
intake assessment, who acted as the care-managers. The
standardized CVD-risk assessment comprised smoking
habit assessment, anthropometric measurement (clinic
BP, body height, body weight and waist circumference)
and blood tests for full lipid profile and fasting plasma
glucose level. To screen for hypertensive complications, an
ECG was performed on each patient and reviewed by
doctors to look for presence of left ventricular hypertrophy
or evidence of cardiac ischaemia; vascular Doppler was
performed by registered nurses to assess for weak or absent
foot pulses signifying peripheral vascular disease; blood
test for creatinine level was used to assess renal function
based on the estimated glomerular filtration rate (eGFR)
calculated by the MDRD formula, whereas spot urine for
protein-to-creatinine ratio (PCR) was collected to look for
significant proteinuria (i.e. urine PCR 10mg/mmol). The
registered nurses also assessed the participants’ self-man-
agement and lifestyle (e.g. diet, exercise, alcohol and self-
monitoring of BP) and drug adherence by pill-counting and
reviewing with each patient whether he or she could
correctly recall the medication regime. Patients were then
stratified into low, medium or high risk groups according to
the 10-year CVD risk calculated from their relevant risk
factors by the Joint British Society 2005 Equation. A multi-
disciplinary team comprising doctors, nurses, dieticians,
physiotherapists and/or occupational therapists would then
deliver individualized management targeted to the patient’s
risk factors, lifestyle and compliance according to stand-
ardized risk-stratified guidelines. Each team member had a
well defined role: the care-manager nurse provided patient
education on hypertension knowledge, self-BPmonitoring,
adherence to drug and lifestyle advices on diet, exercise
and alcohol consumption, informed other team members
on individual patient’s risk profile via electronic reminder
system and referred the patients to respective services by
other team members according to protocol; special smok-
ing cessation counselling sessions were also offered by
nurses to smokers who were motivated to quit smoking;
frontline doctors were responsible for drug therapy titrationr Health, Inc. All rights reserved.
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Twelve-month effects of AMP-HTand overseeing the process of care; dietitians and physi-
otherapists dealt with obesity and impaired glucose homeo-
stasis, whereas occupational therapists managed clinically
significant psychological distress resulting from or contri-
buting to poor BP control (Fig. 1).
On the other hand, patients under usual care would be
continuously managed by GOPCs doctors without the
nurse-led structured risk assessment and risk-guided man-
agement. These patients had access to the same drug
formulary and could still be referred to for physical exam-
ination, laboratory testing and ECG assessment, or to var-Comprehensive assessment - by care-manager nurse
Drug adherence 
and lifestyle
-  Adherence to medication by pill-counting and prescription review
-  Smoking habit, alcohol consumption
-  Diet, exercise
-  Self-monitoring of BP
Physical
examination
-  Blood pressure and pulse
-  Body weight, body height, BMI and waist circumference
-  Foot pulse (by vascular doppler)
Laboratory tests
-  Blood tests for fasting glucose, full lipid profile and renal function tests
-  Urine for protein
-  Electrocardiogram
Risk stratification based on 10 years’ cardiovascular disease risk calculation using JBS 2005
equation [in absence of target-organ-damage (TOD)] - by care-manager nurse
Low risk
(<10%)
Medium risk
(10–20%)
-  Explanation of risk level
-  HT knowledge education, lifestyle advices
-  Coordination of risk-guided management
Low risk
(<10%)
Medium risk
(10–20%)
High risk
(>20% or with TOD)
GOPC doctor for drug
titration
GOPC doctor for
drug titration
GOPC doctor for drug titration
+ add statin if
LDL-C suboptimal 
≥ 160/100 mmHg GOPC doctor for drug titration + RAMP-HT nurse follow-up
≥ 160/100 mmHg +
on ≥ 3 kinds of anti-HT
drugs
Family medicine specialist for further assessment and management
RAMP-HT nurse follow-up 
Other risk-guided interventions:
Patient empowerment programme – offer to all HT patients who are willing to attend
Smoking Counselling and Cessation Programme/Centre – smokers intend to quit
Dietitian – (1) BMI ≥ 27.5kg/m2 for weight reduction and (2) special dietary needs and (3) poor dietary control
despites nursing intervention offered and (4) pre-diabetes
Physiotherapist – BMI ≥ 27.5kg/m2 intend to join weight reduction programme
Integrated Mental Health Programme by occupational therapist – emotional problems
High risk
(>20% or with TOD)
Risk explanation and education - by care-manager nurse
Risk-guided multidisciplinary interventions
Blood pressure
140/90 – 160/100mmHg
IGURE 1 Risk assessment and management programme for hypertension workflow.F Copyright © 2017 Wolters Kluwer
Journal of Hypertensionious allied health professionals services at their doctors’
discretion.
A total of 12234 hypertension patients aged less than 80
years, without existing CVD or diabetes mellitus, with sub-
optimal BP control (i.e. average SBP 140mmHg or average
DBP90mmHg) despite lifestyle or pharmacological inter-
vention, who were enrolled in the RAMP-HT between Octo-
ber 2011 and March 2012 and had clinical outcomes records
collected at 12months frombaselinewere identified from the
Hospital Authority Clinical Management System (CMS). A
total of 10262 out of the 12234 RAMP-HT participants were Health, Inc. All rights reserved.
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atGOPCwhonever enrolled inRAMP-HTonorbefore 30 Jun
2013 using propensity score matching based on social dem-
ographics, drug history, biometric data andpredicted 10-year
CVD risk and the stage of hypertension [18]. The propensity
score mapping was made by using the ‘psmatch2’ command
with one-to-onematchingwithout replacement and a caliper
of 0.001 approach in the STATA. Figure 2 shows the flow of
patient selection and matching in this study. These two
matched cohorts were included in the evaluation of the
effectiveness of RAMP-HT. The dates of baseline for
RAMP-HT participants and usual care group were defined
as the date of enrolment and 31 Oct 2011, respectively, and
the follow-up period for both groups was defined as 12-
month after baseline.
Theprimaryoutcomesof this studywere theproportionof
patients achieving satisfactory BP (SBP< 140mmHg and/or
DBP< 90mmHg), LDL-C (<3.4mmol/l for patients with
predicted CVD risk 20% or <2.6mmol/l for CVD risk
>20%) as recommended by the Hong Kong framework
[19], and the mean changes in predicted 10-year CVD risk
after 12 months of intervention. The secondary outcomes
were the mean changes in the clinical outcomes (SBP, DBP,
LDL-C), the likelihood to improve (post–pre <0) in clinical
outcomes and predicted 10-year CVD risks at a 12-month
follow-up, and the number needed to treat (NNT) to achieve
satisfactory BP and to prevent a predicted CVD event.Remaining RAMP-HT
BP ≥ 140/90mmHg
(n = 12 234)
Matched patients with propensity score matching
(RAMP-HT=10 262, non-RAMP-HT =10 262, total = 20 524)
(Factors:  age,  gender,  smoking  status,  BMI,  BP,  LDL-C,
triglyceride, TC/HDL-C ratio, fasting glucose, eGFR,
Framingham 10-year CVD risk, number of anti-HT drug taken,
lipid-lowering agent, HT stage and BP target)
Non-matched
subjects
(n = 1972)
Remaining Non-RAMP-HT
BP ≥ 140/90mmHg
(n = 29 784)
Non-matched
patients
(n = 19 522)
RAMP-HT
BP ≥ 140/90mmHg
(n = 14 658)
Age ≥ 80/DM/with
CVD complication
(n = 2424)
Non-RAMP-HT
BP ≥ 140/90mmHg
(n = 49 067)
Age ≥ 80/DM/with
CVD complication
(n = 19 283)
IGURE 2 Flow chart of patients matching.F Copyright © 2017 Wolters Kluwe
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ical outcomes data at baseline and 12 months were
extracted from the Hospital Authority CMS. Sociodemo-
graphics included age, sex and smoking habit. Drug history
included the number of antihypertensive drugs prescribed
and the use of lipid lowering agent. Biometric data were BP,
BMI, lipid profile [LDL-cholesterol (LDL-C), total choles-
terol-to-HDL-cholesterol ratio (TC/HDL-C ratio) and trigly-
ceride], fasting glucose and eGFR. The stage of
hypertension was defined according to the Joint National
Committee – Stage I: BP between 140–159/90–99mmHg;
Stage II: BP at least 160/100mmHg [4]. The 10-year pre-
dicted CVD risk was estimated by the total CVD risk of the
Framingham risk prediction function [12]. To avoid the
impact of ageing on CVD risks, we applied the age at
baseline to calculate the CVD risks at both baseline and
12 months. The BP at baseline was defined as the averages
of all available BP readings within 6 months before base-
line, whereas the BP at 12 months was defined as the
averages of all BP measurements between 6 and 18 months
after baseline. All other biometric data at baseline and 12
months were defined as the latest available reading until 3
months and between 6 and 18 months after baseline,
respectively.
Descriptive statistics were used to report the character-
istics of sociodemographics, drug history, biomedical data,
predicted 10-year CVD risk and the stage of hypertension ofr Health, Inc. All rights reserved.
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Twelve-month effects of AMP-HTeach patient in RAMP-HT group and usual care groups at
baseline and after 12 months. Differences in baseline and
12-month characteristics between groups were tested using
independent t tests for continuous variables or chi-square
tests for categorical variables.
To assess the effectiveness of RAMP-HT compared with
usual care after 12 months of intervention, the mean
changes, the proportion of target achievement and
improvements in clinical outcomes (SBP, DBP and LDL-
C) and predicted 10-year CVD risk were evaluated. Paired t
tests were used to evaluate the mean within-patients
changes in the outcomes of interest at 12 months compared
with baseline. Unadjusted difference-in-difference esti-
mation in the outcomes between groups was performed
by independent t tests. The NNT to achieve satisfactory BP
and to prevent a predicted CVD event were calculated.
Adjusted difference-in-difference estimations between
groups were assessed using multiple linear regressions
by the adjustment of confounding factors (sociodemo-
graphics, drug history, biomedical data, predicted 10-year
CVD risk and the stage of hypertension). Similarly, for the
evaluation of the rate of target achievement and improve-
ment in the outcomes, chi-square test was used to test the
unadjusted difference-in-difference in the proportion of
target achievement rate and improvement between groups.
Adjusted difference-in-difference estimations between
groups were assessed using multiple logistic regressions
by the adjustment of confounding factors mentioned above.
All statistical analyses were performed using STATA
version 13.0 (StataCorp LP. College Station, Texas, USA).
All significance tests were two-tailed and findings with a P
value less than 0.05 were considered statistically significant.
Ethics approvals
The current study has received ethics approval from the
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster (UW 13-227),
Hong Kong East Cluster (HKEC-2013-029), Kowloon East
and Kowloon Central Cluster (KC/KE-13-0069/ER-3), Kow-
loon West Cluster [KW/EX-13-082 (64-10)], New Territories
East Cluster (CRE-2013.423) and New Territories West
Cluster (NTWC/CREC/1193/13). The clinical trial number
and registry is NCT02219958, ClinicalTrials.gov.
RESULTS
A total of 20 524 patients, 10 262 from each of the RAMP-HT
group and usual care group, were included in the final data
analysis (Fig. 2). The baseline and 12-month characteristics
of the RAMP-HT participants and usual care hypertension
patients are shown in Table 1. Due to propensity score
matching, the sociodemographics, drug history, biomedical
data, predicted 10-year CVD risk and the stage of hyper-
tension between the two groups were similar at baseline.
All patients had suboptimal BP at least 140/90mmHg at
enrolment, whereas 10% of patients had BP at least 160/
100mmHg. Among these patients, over 98% were taking at
least one antihypertensive medication, whereas the remain-
ing 2% were receiving lifestyle interventions. Approxi-
mately 60% of patients had suboptimal LDL-C control
(i.e. 2.6mmol/l for patients with predicted 10-year CVD Copyright © 2017 Wolters Kluwer
Journal of Hypertensionrisk >20% and 3.4mmol/l for patients with predicted 10-
year CVD risk 20%) at enrolment, but only 10% were
prescribed a lipid-lowering-agent.
After 12 months, significant improvement in SBP (RAMP-
HT: 11.85mmHg; usual care: 11.01mmHg), DBP
(RAMP-HT: 4.12mmHg; usual care: 4.15mmHg), LDL-
C level (RAMP-HT: 0.09mmol/l; usual care: 0.04mmol/
l) and predicted 10-year CVD risks (RAMP-HT: 3.34%;
usual care: 2.96%), were observed in both the RAMP-HT
and usual care group. The observed differences between
the two groups in BP control, LDL-C level and predicted 10-
year CVD risks (SBP: 0.84mmHg, P< 0.01; LDL-C:
0.05mmol/l, P< 0.01; CVD risk: 0.39%, P< 0.01) were
modest yet statistically significant. Significant differences
were observed in the use of antihypertensive drugs and
lipid-lowering agent between RAMP-HT participants and
usual care patients. There were also significantly less cur-
rent smoker and patients with BPmore than 160/100mmHg
in the RAMP-HT group.
Table 2 and Fig. 3 show the target achievement rates,
within-patient changes and improvement rates on clinical
outcomes and predicted 10-year CVD risk from baseline to
after 12 months of both RAMP-HT participants and usual
care patients. Compared with the usual care group, a
significantly greater proportion of RAMP-HT participants
achieved the target BP, SBP, DBP and LDL-C after 12
months (BP: 3.77%, P< 0.01; SBP: 3.61%, P< 0.01; DBP:
0.89%, P¼ 0.011; LDL-C: 2.73%, P< 0.01). The NNT for
patients reaching satisfactory BP control and for reduction
of 1 predicted CVD event were 27 and 204, respectively.
After adjusting for confounding factors, RAMP-HT was
associated with an increased likelihood of target achieve-
ment in BP (OR¼ 1.18, P< 0.01), SBP (OR¼ 1.18, P< 0.01),
DBP (OR¼ 1.21, P< 0.01), LDL-C (OR¼ 1.13, P< 0.01) and
a greater reduction in the predicted 10-year CVD risk
(coefficient¼0.44, P< 0.01).
DISCUSSION
To the best of our knowledge, this is the first study to
evaluate the effectiveness of a structured CVD-risk stratifi-
cation and risk-guided management programme building
on existing clinical resources and available multidiscipli-
nary interventions, as an added-on service to usual care for
patients with hypertension in the real-world primary care
setting. Our results demonstrated that RAMP-HT led to
greater proportion of patients achieving target BP and
LDL-C and greater reduction in predicted 10-year CVD risk
after 12 months of intervention among primary care
patients with suboptimal BP control compared with the
usual care; the difference reached statistical significance.
The RAMP-HT interventions are evidence based [17] and
multifaceted, aiming to address four inter-related com-
ponents of the chronic care model [20] using a multidisci-
plinary team approach. In contrast to traditional doctor-led
idiosyncratic clinical care, the RAMP-HT nurse acts as the
care manager for each RAMP-HT participant and is respon-
sible for providing patient assessment and education, and
coordinating frontline doctors care and allied health pro-
fessionals services according to protocol. In addition to
ensuring the delivery of appropriate treatment tailored to Health, Inc. All rights reserved.
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TABLE 2. Comparisons of the target achievement rates, within-patient changes and improvement rates on clinical outcomes and
predicted 10-year cardiovascular disease risk from baseline to after 12 months of both risk assessment and management
programme for hypertension participants and usual care patients
Clinical outcomes
RAMP-HT
(n¼10262)
Usual care
(n¼10262)
Unadjusted difference-in-
difference
Adjusted difference-in-
difference
Paired
difference/
after 12 months
Paired
difference/
after 12 months
Estimate
(95% CI) P value
Coefficient/odds
ratio (95% CI) P value
Target achievement rates (%, n)
SBP<140mmHg 62.19% 58.54% 3.61% (2.291, 4.920) <0.001 1.18 (1.115, 1.254) <0.001
DBP<90mmHg 14.27% 13.43% 0.89% (0.200, 1.573) 0.011 1.21 (1.077, 1.366) 0.001
SBP/DBP<140/90mmHg 63.92% 60.14% 3.77% (2.444, 5.098) <0.001 1.18 (1.117, 1.253) <0.001
LDL-C<3.4mmol/l (CVD
risk 20%a); <2.6mmol/
l (CVD risk >20%b)
3.63% 1.27% 2.73% (1.076, 4.378) 0.001 1.13 (1.039, 1.223) 0.004
Mean changes
SBP (mmHg) 11.85 11.01 0.84 (1.147, 0.538) <0.001 0.84 (1.099, 0.574) <0.001
DBP (mmHg) 4.12 4.15 0.03 (0.164, 0.224) 0.764 0.02 (0.146, 0.182) 0.828
LDL-C (mmol/l) 0.09 0.04 0.05 (0.073, 0.025) <0.001 0.06 (0.081, 0.039) <0.001
Framingham 10-year
CVD risk (%)
3.34 2.96 0.39 (0.578, 0.197) <0.001 0.44 (0.606, 0.280) <0.001
Improvements (%)c
SBP 87.58% 84.85% 2.73% (1.786, 3.671) <0.001 1.27 (1.166, 1.373) <0.001
DBP 71.89% 72.60% 0.71% (1.937, 0.514) 0.255 0.97 (0.909, 1.038) 0.389
LDL-C<3.4mmol/l (CVD
risk 20%a); <2.6mmol/
l (CVD risk >20%b)
49.68% 47.55% 2.13% (0.468, 3.800) 0.012 1.13 (1.052, 1.213) 0.001
Framingham 10-year
CVD risk
75.72% 74.69% 1.03% (0.405, 2.468) 0.159 1.07 (0.991, 1.160) 0.081
CI, confidence interval; CVD, cardiovascular disease; RAMP-HT, risk assessment and management programme for hypertension.
aFramingham 10-year CVD risk 20%.
bFramingham 10-year CVD risk >20%.
cPre–post >0.
P value of testing significance using independent t test.
P value of testing significance in adjusted difference-in-difference estimate using multiple linear or logistic regressions, as appropriate.
P value of testing significance using paired t test or chi-square test, as appropriate.
Significant differences of P value <0.05.
Twelve-month effects of AMP-HTindividual patient’s needs and risks, these organizational
changes allow focused yet coordinated interventions
according to the expertise of each team members and
are time-saving. Moreover, an electronic clinical data entry
platform is available to enhance relay of information among
the different team members. This feedback system prompts
frontline doctors of the assessment results, enables them to
review the process of care delivered to the respective
patients and to adjust drug prescription as indicated. From
the patient’s perspective, multiple contacts with different
team members help to reinforce knowledge, adherence
and self-management. These strategies were postulated to
contribute to the observed beneficial effect of RAMP-HT on
BP, LDL-C and CVD risk in addition to the effects of various
interventions provided.
Compared with previous studies, the mean BP reduction
achieved in the RAMP-HT group after 12 months (SBP:
11.9mmHg, DBP: 4.12mmHg) was similar to those
found in another cardiovascular risk management pro-
gramme [16] and a nurse-led drug titration and education
intervention [21], but greater than those of a nurse-led drug
titration intervention or multidisciplinary intervention
focusing on lifestyle alone [10,22]. Mendis found that imple-
mentation of the WHO CVD risk management package,
which was a clinical decision support intervention consist-
ing of risk stratification based on age, clinical history of
CVD, diabetes, smoking and SBP and risk-guided drug
therapy and lifestyle advices by primary care doctors Copyright © 2017 Wolters Kluwer
Journal of Hypertensionaccording to standardized protocol, led to greater BP
reduction (SBP: 11.0 to 13.3mmHg; DBP: 5.4 to
6.1mmHg) compared with control [16]. Both Rudd
et al. [21] and Hill et al. [22] evaluated the effect of hyper-
tension drug titration by nurses or community health
workers according to standardized algorithms and demon-
strated that this approach led to greater reduction in BP in a
period of 6–36 months (Rudd: SBP: 14.2mmHg, DBP:
6.5mmHg; Hill: SBP:8.2mmHg; DBP:4.0mmHg); the
greater BP reduction observed in Rudd’s study could be
explained by the additional nurse education on correct use
of self-BP monitoring and drug compliance through tele-
phone consultation [21]. On the other hand, the multi-
disciplinary lifestyle intervention in Mattila’s study led to
only a small but significant reduction in BP compared with
control (SBP: 2.1mmHg, DBP: 1.5mmHg) [10]. Our
findings further supported that algorithm-driven, multidis-
ciplinary CVD risk assessment and risk-guided manage-
ment involving patient education and drug titration was
an effective way to improve BP control and was superior to
lifestyle intervention or drug titration alone.
Significantly, although the RAMP-HT encompassedmore
interventions compared with these previous studies, an
additive effect on BP reduction was not apparent. More-
over, the net difference in BP improvement between the
intervention (RAMP-HT) and control group (usual care)
found in our study (SBP: 0.84mmHg, DBP: 0.03mmHg)
was much smaller than these studies (SBP: 3.74 to Health, Inc. All rights reserved.
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FIGURE 3 Changes between baseline and 12 months on clinical outcomes in risk assessment and management programme for hypertension and non-risk assessment and
management programme for hypertension groups. All differences between baseline and 12 months for risk assessment and management programme for hypertension/
non–risk assessment and management programme for hypertension are significant with P values <0.0001.
Yu et al.8.50mmHg, DBP:1.53mmHg to6.4mmHg), although
the magnitude of improvement remained statistically sig-
nificantly greater in the RAMP-HT group. This could be
explained by the study design and the absence of an
algorithm for hypertension drug titration by frontline
doctors. Our study was an observational cohort study on
the implementation of RAMP-HT as an additional but
integrated component to usual GOPC care in the real-world
primary care setting, as opposed to a randomized con-
trolled trial [17]. First, adherence to RAMP-HT protocol
would not be ideal in the presence of patient’s and doctor’s
barriers. Second, as RAMP-HT was not a stand-alone pro-
gramme, the allied health professional services, patient
education via Patient Empowerment Programme and
laboratory assessment were also accessible to usual care
patients at their doctors’ discretion [23]. Furthermore,
except from the very high-risk group with BP more than
160/100mmHg despite on three or more antihypertensive
medications or features suggestive of secondary hyperten-
sion who would be managed by specialists in family medi-
cine, all the RAMP-HT participants and usual care
hypertension patients were managed by the same group
of primary care doctors working in the different GOPCs
across Hong Kong using the same drug formulary. The only
difference affecting the doctor’s management would be the
availability of feedback from RAMP-HT nurses and allied
health professionals on CVD risks of RAMP-HT participants
but not the usual care group. Because of this arrangement, a
specific algorithm for antihypertensive drug titration only
for RAMP-HT participants would neither be practical nor Copyright © 2017 Wolters Kluwe
634 www.jhypertension.comfeasible. It was also highly probable that participation of
these primary care doctors in the RAMP-HT improved their
awareness on the needs for CVD-risk assessment, drug
titration and referral to allied health services even when
they were providing ‘usual care’ to hypertension patients
not enrolled in RAMP-HT. These factors might bias the
effects of RAMP-HT towards null as nearly comparable
BP improvement was also observed in the usual care group
(SBP: 11.0mmHg; DBP: 4.2mmHg). Nevertheless, con-
sidering that a significantly greater proportion of RAMP-HT
patient achieved target BP than usual care group, which
was a more meaningful outcome than mean BP reduction
for healthcare providers, the clinical benefit of having the
additional RAMP-HT services in addition to usual care and
the use of feedback loop was still evident and important.
In addition to BP control, we demonstrated that RAMP-
HT was also effective in improving LDL-C and CVD risks.
Although hyperlipidaemia often coexists with hypertension
and assessment of total CVD risk has been strongly advo-
cated, very few hypertension intervention studies evaluated
LDL-C or predicted 10-year CVD risk as outcomes of their
interventions [14,15]. In the RAMP-HT, one important com-
ponent of CVD risk management was the prescription of
lipid-lowering agents to participants with highly predicted
10-year CVD risk more than 20% in addition to lifestyle
advices. A significantly higher proportion of RAMP-HT
participants were prescribed lipid-lowering agents after
12 months, possibly prompted by the feedback reminders
on the CMS about the CVD risk of RAMP-HT participants. As
a result, a significantly greater proportion of patients hadr Health, Inc. All rights reserved.
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Twelve-month effects of AMP-HTachieved target LDL-C or improved LDL-C in the RAMP-HT
group compared with the usual care group. Together with
improved BP, the improved lipid profile contributed to a
significantly greater reduction in the predicted 10-year CVD
risks in the RAMP-HT group compared with usual care after
12 months of intervention.
The RAMP-HT is an organizational investment from the
Hospital Authority to improve the quality of hypertension
care in Hong Kong. Our findings confirmed that RAMP-HT,
a protocol-driven multidisciplinary CVD-risk stratification
based management, was effective in improving BP control,
LDL-C and predicted 10-year CVD risk of patients with
suboptimal BP control after 12 months when compared
with usual care. Nevertheless, it was not yet certain if the
observed benefits could be extrapolated to patients with
stable control hypertension. Also, BP and LDL-C were only
surrogate CVDmarkers. Therefore, a longer term follow-up
is required to evaluate whether the intervention can lead to
actual reduction in CVD events and to validate the effec-
tiveness of RAMP-HT among different risk groups over a
longer time span. The long-term impact of RAMP-HT on
noncardiovascular complications such as renal failure and
on healthcare resources and service utilization is yet to be
evaluated. To attain the desired health benefits of the
RAMP-HT in the real-world clinical setting, one must also
ensure that the intended care has been provided; annual
evaluation of quality of care and feedback on possible areas
of improvement are essential.
Our study had several limitations. First, evaluation of the
RAMP-HT was designed as a population-based matched
cohort study as opposed to an experimental randomized
control study. The aim of RAMP-HT is to improve popu-
lation BP control through an optimized, coordinated use of
existing resources in the public primary care setting; such
set-up requires concerted efforts from various stakeholders
including health policy-makers, frontline healthcare pro-
viders and patients with continual feedback from the
research team to ensure its implementation in the real-
world clinical setting. Therefore, conducting a participa-
tory-action research instead of randomized control trial is
the most appropriate, although it is well aware that unob-
served potential confounders may affect the results, and
blinding of healthcare providers and patients is not
possible. Moreover, literatures had shown that similar
results could be obtained from observational studies and
RCTs. Second, not all the RAMP-HT participants nor usual
care hypertension patients were included in the analysis.
Patients with missing clinical or demographic data were
excluded, and it was most possible that hypertension
patients receiving suboptimal ‘usual care’ would not even
have clinical or laboratory data to be included in the data
analysis. Some RAMP-HT participants who could not be
matched to control pairs were excluded at the matching
phase. These may have biased the potential benefits of
RAMP-HT. In addition, some patients with satisfactory BP
control were enrolled into RAMP-HT during the studied
period; we did not include them in our analysis because we
hypothesized that these RAMP-HT participants would not
be receiving additional RAMP-HT interventions to usual
care in view of their good BP. Conversely, patients older
than 80 years were excluded because BP and LDL-C targets Copyright © 2017 Wolters Kluwer
Journal of Hypertensionfor the elderly group remain controversial. Lastly, the
predicted 10-year CVD risk, but not the incidence of
CVD events, was evaluated in this study because a 12-
month follow-up period was too short to observe CVD
events. The predicted 10-year CVD risk was estimated by
the Framingham function, which was derived from the US
population. Yet, there is currently no CVD-risk prediction
function available for Chinese hypertension patients. Thus,
the estimated benefit in CVD-risk reduction may not be
accurate. Further study with a longer follow-up period (e.g.
5 years) is needed to confirm the effectiveness of RAMP-HT
by observed clinical events and whether such intervention
is cost-effective.
In conclusion, among patients with suboptimal hyper-
tension control, such structured, protocol-driven multidis-
ciplinary RAMP-HT was more effective than usual care in
achieving satisfactory control of BP and LDL-C, and reduc-
ing predicted 10-year CVD risk after 12 months of inter-
vention. Long-term evaluation should be conducted to
assess whether improvement in the clinical outcomes can
be translated into actual reduction in CVD complications
and mortalities in the real-world clinical setting, and
whether the intervention is cost-effective.
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Reviewer 1
The Risk-Assessment-and-Management-Programme for
patients with Hypertension (RAMP-HT) study tested the
potential effects of a protocol-driven multidisciplinary risk
assessment and management program in a large cohort of
hypertensive patients at low-moderate risk (without dia-
betes or other comorbidities), who did not achieve optimal
control of blood pressure and low-density lipoprotein
cholesterol levels. The study demonstrated that this
approach was more effective than usual care in achieving
satisfactory control of BP and LDL-C levels, and reducing
predicted 10-years cardiovascular risk at 12-month follow-
up observation. Such educational and therapeutic strategy
can be effectively applied in a setting of real practice,
although in some selected Countries several economic
limitations and regulatory rules may at least, in part, limit
the clinical effectiveness of this approach.Reviewer 2
The authors successfully implemented a nonrandomized
multidisciplinary assessment-and-management program
(RAMP-HT) for treated but uncomplicated hypertension
with suboptimal BP control in primary care. RAMP-HT
significantly improved the proportion of patients achieving
target levels of SBP and LDL-cholesterol and reduced
predicted 10-y Framingham CVD risk versus usual care
after 12 months follow-up. However, the absolute differ-
ence between SBP, LDL-C and risk reductions comparing
both strategies is very small. It remains to be proven
whether implementation of such a nurse-led multidiscipli-
nary program as an additional but integrated component of
usual care in drug-treated hypertension with suboptimal BP
will translate into considerable less CV events at a reason-
able cost–benefits ratio.r Health, Inc. All rights reserved.
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